Mabwell(SH:688062) Zheng Quan Zhi Xing·2025-06-26 16:51Group 1 - The board of directors of Maiwei (Shanghai) Biotechnology Co., Ltd. held its 19th meeting of the second session on June 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1][2]. - The board approved a share repurchase plan via centralized bidding, aimed at enhancing investor confidence and promoting the stock price's return to its intrinsic value [1][2]. - The board also approved an exclusive licensing agreement with CALICO LIFE SCIENCES LLC, which aligns with the company's strategic development goals and is expected to positively impact its ongoing operations [2][3]. Group 2 - The board approved a technical licensing agreement for the new drug project involving injectable Agrestin α, which is expected to leverage mutual strengths and resources between the company and its partner, promoting long-term development [3]. - The board agreed to convene the company's first extraordinary general meeting of 2025 for further deliberation on the approved proposals [3].